Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib prophylaxis for severe aGVHD in pediatric HSCT (daGOAT model)
NCT05599256Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05599256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599256.